The DOI matches its Crossref record.
LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
Open accessOverview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA rarely approves chemoimmunotherapeutic strategies with other α-PD-1 drugs (except for nivolumab combined with chemotherapy for gastric cancer and GEJC) [58].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [58]
Citations
Cited by
Sorted by citations
Current treatment and recent progress in gastric cancer
Joshi, S. S., & Badgwell, B. D. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21657 · Cited by 1,740
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
“strategies with other α-PD-1 drugs (except for nivolumab combined with chemotherapy for gastric cancer and GEJC) [58].”
InfluentialMorgan, E., Soerjomataram, I., Rumgay, H., Coleman, H. G., Thrift, A. P., Vignat, J., Laversanne, M., Ferlay, J., & Arnold, M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.05.054 · Cited by 1,242
Wang, F., Zhang, X., Li, Y., Tang, L., Qu, X., Ying, J., Zhang, J., Sun, L., Lin, R., Qiu, H., et al. (2021) · 癌症：英文版 · doi:10.1002/cac2.12193 · Cited by 619
“and treatment response, which was also confirmed in the CheckMate649 study [164].”
BackgroundResultSelf-citationHanna, N. H., Schneider, B. J., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03022 · Cited by 467
Metadata
- Authors
- Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., Schenker, M., Yanez, P., Tehfe, M., Poulart, V., Cullen, D., Lei, M., Kondo, K., Li, M., Ajani, J. A., & Janjigian, Y. Y.
- Affiliations
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- National Cancer Center Hospital East (JP)
- Fundación Arturo López Pérez (CL)
- Peking University Cancer Hospital (CN)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- The Cancer Institute Hospital (JP)
- Medical University of Lublin (PL)
- Fudan University (CN)
- Universidad de La Frontera (CL)
- Centre Hospitalier de l’Université de Montréal (CA)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 31
- Pages
- S1191
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3088611248
- Cited by
- 208
- References
- 0
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 7 · 2023: 19 · 2022: 53 · 2021: 107 · 2020: 11
- FWCI
- 26.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Keywords
- nivolumab, PD-1 inhibitors, advanced gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma, first-line chemotherapy, PD-L1 combined positive score, overall survival, progression-free survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
